Drug Profile
Research programme: glycogen synthase kinase 3 beta inhibitor monoclonal antibodies - DiaMedica Therapeutics
Alternative Names: anti-glycogen synthase kinase 3 monoclonal antibodies - DiaMedica Therapeutics; DM 204Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator DiaMedica
- Developer DiaMedica; DiaMedica Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Bradykinin B2 receptor agonists; Glycogen synthase kinase 3 beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
- Discontinued Cancer; Hypercholesterolaemia; Hypertension; Influenza virus infections; Tularaemia; Viral infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Canada (Parenteral)
- 29 Dec 2016 DiaMedica is now called DiaMedica Therapeutics
- 10 Jun 2014 Discontinued - Preclinical for Cancer in Canada (unspecified route)